News for Cellectar Biosciences, Inc. (CLRB)

Transaction Overview On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a strategic decision to reduce its holdings in Cellectar B

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming  Biotech Showcase during the JP Morgan Healthcare Conference

Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-Wa

Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.22%

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 300 points on Wednesday. The Dow traded up 0.49% to 44,296.79 whi...

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 1% on Wednesday. Following the market opening Wednesday, the Dow tra...

Cellectar (CLRB) stock plunged 50% post-market after the company announced it plans to lay off around 60% of its workforce as it seeks a partner or buyer for its lead asset.

**media[488858]**

Cellectar Biosci stock hits 52-week low at $1.38

Nov 18, 2024 / 01:30PM GMTOperator Ladies and gentlemen, thank you for standing by. (Operator Instructions) Please be advised that today's conference call may b

The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...

Ependymoma Market [2022-2030] Research Report Analysis and Outlook Insights | Latest Updated Report | The Ependymoma Market research report analyses the...

The dynamics of the osteosarcoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising...

Marginal Zone Lymphoma Pipeline constitutes 40+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies,...

Read Oppenheimer Comments on Cellectar Biosciences, Inc.’s Q1 2023 Earnings (NASDAQ:CLRB) at ETF Daily News

Read Analysts’ New Coverage for May 29th (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News

Read Investment Analysts’ New Coverage for May 21st (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au...